Want bang for your buck? Don't look to Sarepta's pricey DMD therapy Exondys, ICER says

23rd May 2019 Uncategorised 0

As far as troubled backstories go, Sarepta Therapeutics’ Exondys 51 has a doozy with a contentious approval process and a major insurer backing away from the targeted therapy. Now the pricey Duchenne muscle dystrophy (DMD) treatment has a new problem: An influential gatekeeper says it simply isn’t cost-effective.

More: Want bang for your buck? Don't look to Sarepta's pricey DMD therapy Exondys, ICER says
Source: fierce